BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 12011652)

  • 1. Effects of orally applied candesartan cilexetil on central responses to angiotensin II in conscious rats.
    Gohlke P; Von Kügelgen S; Jürgensen T; Kox T; Rascher W; Culman J; Unger T
    J Hypertens; 2002 May; 20(5):909-18. PubMed ID: 12011652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripherally applied candesartan inhibits central responses to angiotensin II in conscious rats.
    Gohlke P; Kox T; Jürgensen T; von Kügelgen S; Rascher W; Unger T; Culman J
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Jun; 365(6):477-83. PubMed ID: 12070762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats.
    Gohlke P; Weiss S; Jansen A; Wienen W; Stangier J; Rascher W; Culman J; Unger T
    J Pharmacol Exp Ther; 2001 Jul; 298(1):62-70. PubMed ID: 11408526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan.
    Fabiani ME; Dinh DT; Nassis L; Casley DJ; Johnston CI
    Am J Hypertens; 2000 Sep; 13(9):1005-13. PubMed ID: 10981551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats.
    Paull JR; Widdop RE
    J Hypertens; 2001 Aug; 19(8):1393-402. PubMed ID: 11518847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of angiotensin, AT1 and AT2 receptors in the pressor, drinking and vasopressin responses to central angiotensin.
    Hogarty DC; Speakman EA; Puig V; Phillips MI
    Brain Res; 1992 Jul; 586(2):289-94. PubMed ID: 1521162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central mineralocorticoid receptors and the role of angiotensin II and glutamate in the paraventricular nucleus of rats with angiotensin II-induced hypertension.
    Gabor A; Leenen FH
    Hypertension; 2013 May; 61(5):1083-90. PubMed ID: 23509081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
    Fridman K; Andersson OK; Wysocki M; Friberg P; Sunzel M
    Eur J Clin Pharmacol; 1998 Sep; 54(7):497-501. PubMed ID: 9832289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats.
    Culman J; von Heyer C; Piepenburg B; Rascher W; Unger T
    Eur J Pharmacol; 1999 Feb; 367(2-3):255-65. PubMed ID: 10079000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of a centrally-mediated antihypertensive effect following acute or chronic central treatment with AT1-receptor antagonists in spontaneously hypertensive rats.
    Bunting MW; Widdop RE
    Br J Pharmacol; 1995 Dec; 116(8):3181-90. PubMed ID: 8719794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renin-angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism.
    Brilla CG; Scheer C; Rupp H
    J Hypertens Suppl; 1997 Dec; 15(6):S13-9. PubMed ID: 9493122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan.
    Azizi M; Chatellier G; Guyene TT; Ménard J
    J Hypertens; 1999 Apr; 17(4):561-8. PubMed ID: 10404959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of acute AT1 receptor blockade by candesartan on arterial pressure and renal function in rats.
    Cervenka L; Wang CT; Navar LG
    Am J Physiol; 1998 May; 274(5):F940-5. PubMed ID: 9612332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microinjections of angiotensin II into the supraoptic and paraventricular nuclei produce potent antidiureses by vasopressin release mediated through adrenergic and angiotensin receptors.
    Tsushima H; Mori M; Matsuda T
    Jpn J Pharmacol; 1994 Oct; 66(2):241-6. PubMed ID: 7869608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional role of brain AT1 and AT2 receptors in the central angiotensin II pressor response.
    Toney GM; Porter JP
    Brain Res; 1993 Feb; 603(1):57-63. PubMed ID: 8453478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
    Hübner R; Högemann AM; Sunzel M; Riddell JG
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats.
    Wada T; Inada Y; Ojima M; Sanada T; Shibouta Y; Nishikawa K
    Hypertens Res; 1996 Jun; 19(2):75-81. PubMed ID: 10968199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of blockade of AT1 and AT2 receptors in brain on the central angiotensin II pressor response in conscious spontaneously hypertensive rats.
    Toney GM; Porter JP
    Neuropharmacology; 1993 Jun; 32(6):581-9. PubMed ID: 8336821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral administration of an AT1 receptor antagonist prevents the central effects of angiotensin II in spontaneously hypertensive rats.
    Seltzer A; Bregonzio C; Armando I; Baiardi G; Saavedra JM
    Brain Res; 2004 Nov; 1028(1):9-18. PubMed ID: 15518636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Candesartan cilexetil: pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist].
    Inada Y; Naka T
    Nihon Yakurigaku Zasshi; 2000 Mar; 115(3):151-60. PubMed ID: 10876800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.